Full Breakdown
Bayer Acquires Perfuse Therapeutics in $2.45 B Deal to Bolster Ophthalmology Portfolio
5/6/2026, 10:40:48 PM
Bayer-Perfuse Deal Overview
On 6 May 2026, German pharmaceutical group Bayer announced the acquisition of San Francisco-based biotech Perfuse Therapeutics. The transaction provides Bayer with an upfront cash payment of $300 million and potential milestone payments that could raise total consideration to $2.45 billion, subject to regulatory clearance and Perfuse shareholder approval. Bayer will obtain full rights to PER-001, a small-molecule endothelin-receptor antagonist delivered via a bio-erodible intravitreal implant and currently in Phase II development for glaucoma and diabetic retinopathy.
Strategic Context and Recent M&A Activity
The purchase marks Bayer’s first biopharma acquisition since the 2021 purchase of Vividion Therapeutics. After a multi-year turnaround plan launched under CEO Bill Anderson in 2023, Bayer has focused on cost reduction and licensing deals, while its flagship eye drug Eylea generated €3.1 billion in 2025—a 5.9 % decline driven by biosimilar competition and price pressure in key markets. The Perfuse deal is positioned to diversify Bayer’s ophthalmology pipeline and address anticipated growth in vision-loss disorders.
Principal Stakeholders
- Bayer AG – Global life-science corporation, pharmaceuticals division.
- Perfuse Therapeutics – Clinical-stage biotech developing PER-001.
- Juergen Eckhardt – Head of Business Development & Licensing, Bayer Pharmaceuticals.
- Sevgi Gurkan – Chief Executive Officer, Perfuse Therapeutics.
- Regeneron Pharmaceuticals – Partner on Bayer’s existing VEGF inhibitor Eylea.
Deal Metrics and Disease Burden
- Up-front payment: $300 million; total potential payout: $2.45 billion.
- PER-001: Phase IIa trials reported reversal of progressive vision loss in glaucoma and improvements in retinal ischemia for diabetic retinopathy.
- Global prevalence (Bayer estimates): ~80 million with glaucoma; ~146 million with diabetic retinopathy.
- Eylea 2025 revenue: €3.1 billion (?$3.6 billion).
Implications for Bayer’s Ophthalmology Business
PER-001 targets the endothelin pathway, a mechanism not exploited by existing eye-drug classes, and could become one of the first disease-modifying treatments for the two leading causes of blindness. If successful, the asset may offset Eylea’s declining sales and expand Bayer’s portfolio beyond anti-VEGF therapies. The acquisition also provides Bayer with an intravitreal-implant platform that could be adapted to other retinal conditions, such as dry age-related macular degeneration and retinal vein occlusion, currently in pre-clinical evaluation.
Official Statements Summarized
Bayer’s Juergen Eckhardt emphasized that the transaction “complements our expertise in ophthalmology and reinforces our commitment to urgently needed therapies.” Perfuse CEO Sevgi Gurkan noted alignment of vision between the companies and highlighted Bayer’s capacity to “unlock the full potential of PER-001.” Both parties framed the deal as a strategic step toward addressing unmet needs in glaucoma and diabetic retinopathy.
Conflicting Reports and Information Gaps
Sources differ on the specificity of milestone criteria, describing them as “unspecified development, regulatory and commercial benchmarks.” No definitive closing date has been disclosed, and detailed plans for post-acquisition development of PER-001 remain absent.
Verbatim Quotes
- “With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients,” — Juergen Eckhardt, Head of Business Development & Licensing, Bayer Pharmaceuticals
- “We are excited by the work of the team at Perfuse Therapeutics and encouraged by the potential of PER-001,” — Juergen Eckhardt, Head of Licensing, Bayer Pharmaceuticals
- “San Francisco-based Perfuse's chief executive, Sevgi Gurkan, said: "Bayer's vision aligns with ours, and they have the scale and global resources to unlock the full potential of PER-001 to change the trajectory of human blindness.” — Sevgi Gurkan, Chief Executive Officer, Perfuse Therapeutics
Future Milestones
The deal awaits antitrust clearance and Perfuse shareholder approval. Bayer plans to initiate a Phase IIb/III trial of PER-001 in the second half of 2025, contingent on regulatory endorsement. Milestone payments will be triggered by achievement of predefined development, regulatory, and commercial targets, potentially bringing total consideration to the $2.45 billion ceiling.
